Gensight Biologics S.a annual net income
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Net Income Growth & History (SIGHT)
Gensight Biologics S.a's net income was −€12.0M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€12.0M | €2.0M | — |
| 2024 | 2024-12-31 | −€14.0M | €12.2M | — |
| 2023 | 2023-12-31 | −€26.2M | €1.4M | — |
| 2022 | 2022-12-31 | −€27.6M | €992,000 | — |
| 2021 | 2021-12-31 | −€28.6M | €5.4M | — |
| 2020 | 2020-12-31 | −€34.0M | — | — |
Gensight Biologics S.a net income trends
Over the last five fiscal years, Gensight Biologics S.a's net income increased from −€34.0M to −€12.0M, a change of €22.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company official filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...